Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker FDMT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). NCT07867080 · Diabetic Macular Edema (DME) 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2… | FDMT 4D Molecular Therapeutics | Phase 3 | Recruiting | 514 | Jan 2029 | Registry ↗ |
| Oct 26, 2026 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration NCT06864988 · Macular Neovascularization Secondary to Age-Related Macular… 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2… | FDMT 4D Molecular Therapeutics | Phase 3 | Active, not recruiting | 480 | Jun 2027 | Registry ↗ |
| Oct 19, 2026 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary… NCT07064759 · Neovascular Age-Related Macular Degeneration (nAMD) 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2… | FDMT 4D Molecular Therapeutics | Phase 3 | Recruiting | 480 | Nov 2027 | Registry ↗ |
| Aug 21, 2026 | 4D-150 in Patients With Diabetic Macular Edema NCT05930561 · Diabetic Macular Edema, Diabetic Retinopathy 4D-150 IVT, Aflibercept IVT | FDMT 4D Molecular Therapeutics | Phase 2 | Active, not recruiting | 72 | Feb 28, 2029 | Registry ↗ |
| Aug 21, 2026 | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration NCT05197270 · Neovascular (Wet) Age-Related Macular Degeneration 4D-150 IVT, Aflibercept IVT | FDMT 4D Molecular Therapeutics | Phase 1/2 | Recruiting | 215 | Mar 2027 | Registry ↗ |
| Jul 6, 2026 | 4D-710 in Adult Patients With Cystic Fibrosis NCT05248230 · Cystic Fibrosis Lung 4D-710 | FDMT 4D Molecular Therapeutics | Phase 2 | Recruiting | 30 | Jun 2027 | Registry ↗ |
| May 22, 2025 | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia NCT04483440 · Choroideremia 4D-110 | FDMT 4D Molecular Therapeutics | Phase 1 | Active, not recruiting | 13 | May 26, 2027 | Registry ↗ |
| Mar 21, 2025 | 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) NCT04517149 · X-Linked Retinitis Pigmentosa 4D-125 IVT Injection, Observational | FDMT 4D Molecular Therapeutics | Phase 1/2 | Active, not recruiting | 21 | Jun 2026 | Registry ↗ |
| Feb 21, 2025 | 4D-310 in Adults With Fabry Disease and Cardiac Involvement NCT05629559 · Fabry Disease 4D-310 | FDMT 4D Molecular Therapeutics | Phase 1/2 | Recruiting | 18 | Jun 2026 | Registry ↗ |
| Apr 8, 2024 | An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease NCT04519749 · Fabry Disease 4D-310 | FDMT 4D Molecular Therapeutics | Phase 1/2 | Active, not recruiting | 18 | Jan 2026 | Registry ↗ |
| Jan 6, 2022 | "Natural History" Study of Choroideremia NCT02994368 · Choroideremia Observation | FDMT 4D Molecular Therapeutics | — | Terminated | 57 | Oct 2021 | Registry ↗ |
11 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances